Association of HPV viral load, estrogen receptor α signaling, and inflammatory serum biomarkers with cervical cancer progression
Abstract
The persistence of HPV is a high-risk factor of cervical cancer development, although the development of the disease is highly dependent on estrogen receptor signaling and HPV-associated serum biomarkers that have a synergistic effect in promoting the development of malignancy. The aim of the study is examine the relationship between HPV viral load, e s trogen receptor expression, and the presence of serum biomarkers and their interactive effects in the development of cerv i cal cancer. The case control study was carried out in one of the tertiary teaching hospitals in Iraq in the period between January 2024 and January 2025 involving 100 women diagnosed with cervical cancer via histopathology and 50 age-matched healthy women as controls. ELISA and immunohistochemistry methods were used to measure serum estradiol , CA-125, IL-6, TNF-α and CRP, and high-risk HPV viral load was measured using the qPCR , after obtaining ethical a p p roval . The findings showed that there is similarity in the age distribution of the cervical cancer patients and the control with body mass index and parity being significantly higher in the former. There were significant differences in the HPV viral load and ER of high-grade cases as compared to low-grade. Patients especially with high viral load had high levels of serum estradiol , CA-125, IL-6, TNF -α, and CRP. C orrelation analysis showed that there were strong positive links between the HPV load, hormonal activity, the presence of inflammatory biomarkers, and the aggressiveness of the tumor s , demonstra t ing the combined effect of all the factors in cervical cancer development. The interplay between increased HPV viral load and estrogen receptor signaling and general systemic inflammation leads to the cervical cancer progression. High hormonal and inflammatory biomarkers probably encourag e tumor growth and aggressiveness through the effects of su p porting viral persistence, dysregulation of the immune system, and oncogenic pathways that depend on estrogen.References
Bahadoran, E., Rahmani, B., Nazari, E., Hosseinnezhad, A., & Samiee Rad, F. (2025). Comparison of diagnostic methods in patients with squamous intraepithelial lesion in women infected with multiple high-risk human papillomaviruses. Iranian Journal of Pathology, 20(1), 107–116.
Borowczak, J., Szczerbowski, K., Maniewski, M., Kowalewski, A., Janiczek-Polewska, M., Szylberg, A., Marszałek, A., & Szylberg, Ł. (2022). The role of inflammatory cytokines in the pathogenesis of colorectal carcinoma – recent findings and review. Biomedicines, 10(7), 1670.
Farahani, P. K., Azadbakht, M., & Hassanzadeh Kiabi, F. (2025). Postoperative inflammatory dynamics in sleeve gastrectomy: A systematic review and meta-analysis of CRP and TNF-α trends. International Journal of Surgery, 112(2), 5087–5100.
Fobian, S., Mei, X., Crezee, J., Snoek, B. C., Steenbergen, R. D. M., Hu, J., Ten Hagen, T. L. M., Vermeulen, L., Stalpers, L. J. A., & Oei, A. L. (2024). Increased human papillomavirus viral load is correlated to higher severity of cervical disease and poorer clinical outcome: A systematic review. Journal of Medical Virology, 96(6), e29741.
Georgievska, J., Tofoski, G., Dimitrov, G., Daneva-Markova, A., Jovanovska, V., Dabeski, D., Jovcevski, S., Dzikova, E., & Atanasova, A. (2022). The role of some inflammatory markers, cytokins and tumor markers in diagnosis of endometriosis. Archives of Public Health, 14(2), 58–71.
Ghazi, M., Hassan, E., Ibrahim, N., & Mohsein, O. (2025). Early detection of prostate cancer using novel ELISA-based biomarkers: Insights into inflammatory and tumor-specific pathways. Asian Pacific Journal of Cancer Prevention, 26(10), 3833–3839.
Guo, H., Feng, S., Li, Z., Yin, Y., Lin, X., Yuan, L., Sheng, X., & Li, D. (2023). Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy. Journal of Inflammation Research, 16, 5145–5156.
Hakim, R. U., Amin, T., & Ul Islam, S. M. B. (2025). Advances and challenges in cervical cancer: From molecular mechanisms and global epidemiology to innovative therapies and prevention strategies. Cancer Control, 32, 1–31.
Harsanyi, S., Kupcova, I., Danisovic, L., & Klein, M. (2022). Selected biomarkers of depression: What are the effects of cytokines and inflammation? International Journal of Molecular Sciences, 24(1), 578.
Huang, J., Deng, Y., Boakye, D., Tin, M. S., Lok, V., Zhang, L., Lucero-Prisno, D. E., Xu, W., Zheng, Z.-J., Elcarte, E., Withers, M., & Wong, M. C. S. (2022). Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis. Gynecologic Oncology, 164(1), 85–92.
Kliber-Gałuszka, M., Kulczyńska-Figurny, K., Jagodziński, P. P., & Pławski, A. (2025). Potential biomarkers for early detection of endometriosis: Current state of art (what we know so far). Journal of Applied Genetics, 66, in press.
Kothari, A. (2024). HPV-associated head and neck cancer: Etiology and determinants of radiation sensitivity. Doctoral dissertation. University of North Carolina at Chapel Hill, Chapel Hill.
Läsche, M., Gallwas, J., & Gründker, C. (2022). Like brothers in arms: How hormonal stimuli and changes in the metabolism signaling cooperate, leading HPV infection to drive the onset of cervical cancer. International Journal of Molecular Sciences, 23(9), 5050.
Li, J., Niu, C., Zhang, L., Mu, Y., & Gui, X. (2024). Association of body composition and systemic inflammation for patients with locally advanced cervical cancer following concurrent chemoradiotherapy. Diagnostic and Interventional Radiology, 30(5), 279–290.
Li, Q., Cheng, Q., Tian, D., An, Z., Li, L., Yang, F., Zhang, M., Liu, G., Peixin, A., Yang, Y., & Chen, Z. (2025). Study on the detection rate, genetic polymorphism, viral load, persistent infection capacity, and pathogenicity of human papillomavirus type 33. Virology Journal, 22, 121.
Martinelli, M., Giubbi, C., Saderi, L., Musumeci, R., Perdoni, F., Leone, B. E., Fruscio, R., Landoni, F., Piana, A., Sotgiu, G., & Cocuzza, C. E. (2023). Evaluation of human papilloma virus (HPV) genotyping and viral load determination as diagnostic biomarkers of cervical cancer risk. International Journal of Molecular Sciences, 24(2), 1320.
Mir, B. A., Ahmad, A., Farooq, N., Priya, M. V., Siddiqui, A. H., Asif, M., Manzoor, R., Ishqi, H. M., Alomar, S. Y., & Rahaman, P. F. (2023). Increased expression of HPV-E7 oncoprotein correlates with a reduced level of pRb proteins via high viral load in cervical cancer. Scientific Reports, 13(1), 15075.
Mishra, B., Tiwari, A., & Mishra, S. (2024). Metabolic changes and immunity suppression parameters as biomarkers of environmental pollutants. In: Izah, S. C., Ogwu, M. C., & Hamidifar, H. (Eds.). Biomonitoring of pollutants in the Global South. Springer, Singapore. Pp. 693–719.
Pavone, G., Marino, A., Fisicaro, V., Motta, L., Spata, A., Martorana, F., Spampinato, S., Celesia, B. M., Cacopardo, B., Vigneri, P., & Nunnari, G. (2024). Entangled connections: HIV and HPV interplay in cervical cancer – a comprehensive review. International Journal of Molecular Sciences, 25(19), 10358.
Porter, V. L., & Marra, M. A. (2022). The drivers, mechanisms, and consequences of genome instability in HPV-driven cancers. Cancers, 14(19), 4623.
Qi, S.-Y., Yang, M.-M., Li, C.-Y., Yu, K., & Deng, S.-L. (2024). The HPV viral regulatory mechanism of TLRs and the related treatments for HPV-associated cancers. Frontiers in Immunology, 15, 1407649.
Ramadan, A., Hemida, R., Mehanna, E., & Abo-El-Matty, D. (2022). Interleukins (IL-1A and IL-6) and the risk of endometrial carcinoma. Records of Pharmaceutical and Biomedical Sciences, 6(1), 124–135.
Rani, J., Yadav, S., Yadav, R., & Chhabra, R. (2025). Hormonal dynamics of cervical cancer: Role of estrogen and progesterone. Cell Biochemistry and Function, 43(5), e70082.
Reza, S., Anjum, R., Khandoker, R. Z., Khan, S. R., Islam, Md. R., & Dewan, S. M. R. (2024). Public health concern-driven insights and response of low- and middle-income nations to the World Health Organization call for cervical cancer risk eradication. Gynecologic Oncology Reports, 54, 101460.
Singh, D., Vignat, J., Lorenzoni, V., Eslahi, M., Ginsburg, O., Lauby-Secretan, B., Arbyn, M., Basu, P., Bray, F., & Vaccarella, S. (2023). Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. The Lancet Global Health, 11(2), e197–e206.
Swase, T. D., Fasogbon, I. V., Eseoghene, I. J., Etukudo, E. M., Mbina, S. A., Joan, C., Dangana, R. S., Anyanwu, C., Vandu, C. D., Agbaje, A. B., Shinkafi, T. S., Abubarkar, I. B., & Aja, P. M. (2025). The impact of HPV/HIV co-infection on immunosuppression, HPV genotype, and cervical cancer biomarkers. BMC Cancer, 25, 202.
Wolf, J., Kist, L. F., Pereira, S. B., Quessada, M. A., Petek, H., Pille, A., Maccari, J. G., Mutlaq, M. P., & Nasi, L. A. (2024). Human papillomavirus infection: Epidemiology, biology, host interactions, cancer development, prevention, and therapeutics. Reviews in Medical Virology, 34(3), e2537.
Xiao, Q., Liu, Y., Shu, X., Li, Y., Zhang, X., Wang, C., He, S., Li, J., Li, T., Liu, T., & Liu, Y. (2025). Molecular mechanisms of viral oncogenesis in haematological malignancies: perspectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling. Experimental Hematology and Oncology, 14, 69.
Zhang, Y., Qiu, K., Ren, J., Zhao, Y., & Cheng, P. (2025). Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use. Signal Transduction and Targeted Therapy, 10, 44.
Zhou, Y., Shi, X., Liu, J., & Zhang, L. (2023). Correlation between human papillomavirus viral load and cervical lesions classification: A review of current research. Frontiers in Medicine, 10, 1111269.
Zhou, Z.-W., Long, H.-Z., Xu, S.-G., Li, F.-J., Cheng, Y., Luo, H.-Y., & Gao, L.-C. (2022). Therapeutic effects of natural products on cervical cancer: Based on inflammatory pathways. Frontiers in Pharmacology, 13, 899208.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
